DRUG PRODUCT MANUFACTURING

Syngene concludes the acquisition of biologics manufacturing facility from Stelis Biopharma Ltd

As previously announced on July 4, 2023, Syngene International has completed the acquisition of a multi-modal biologics production plant from Stelis Biopharma Ltd. After revisions to the original gross value of Rs 702 crores, the acquisition of the biologics production facility known as "Unit 3" was finalised at a revised gross value of Rs 617 crores.The retention of some equipment that Stelis Biopharma Ltd. does not currently have installed in the plant is reflected in the decrease in gross value.